TY - JOUR
T1 - Patients with unresectable hepatocellular carcinoma beyond Milan criteria
T2 - Should we perform transarterial chemoembolization or liver transplantation?
AU - Kim, J. M.
AU - Kwon, C. H.D.
AU - Joh, J. W.
AU - Kim, S. J.
AU - Shin, M.
AU - Kim, E. Y.
AU - Moon, J. I.
AU - Jung, G. O.
AU - Choi, G. S.
AU - Lee, S. K.
PY - 2010
Y1 - 2010
N2 - Patients with unresectable, beyond Milan criteria, hepatocellular carcinoma (HCC) invariably undergo palliative transarterial chemoembolization (TACE). The aim of this study was to compare the outcomes of conventional TACE versus liver transplantation (LT) in unresectable (beyond Milan criteria) HCC. Twelve patients underwent LT and 86 TACE for unresectable, beyond Milan criteria HCC. The inclusion criteria were a single tumor ≤6.5 cm or ≤5 tumors and all tumors ≤5 cm based on initial radiologic findings. We excluded patients with double primary cancers, age >60 years, vascular invasion, or extrahepatic spread. Survival rates were calculated using the Kaplan-Meier method. Multivariate analysis showed that TACE was a prognostic factor for survival (hazard ratio, 16.66, P =.000). The LT group showed significantly better survival than the TACE cohort. Two cases (16.7%) in the LT group recurred at a median time of 13.5 months. Survival rates at 1, 3, and 5 years were 100%, 88.9%, and 76.2% in the LT group, and 85.6%, 45.6%, and 21.4% in the TACE group, respectively. Patients with unresectable, beyond Milan criteria HCC should be given the option to receive LDLT, because LT offers a significantly better likelihood of survival than TACE.
AB - Patients with unresectable, beyond Milan criteria, hepatocellular carcinoma (HCC) invariably undergo palliative transarterial chemoembolization (TACE). The aim of this study was to compare the outcomes of conventional TACE versus liver transplantation (LT) in unresectable (beyond Milan criteria) HCC. Twelve patients underwent LT and 86 TACE for unresectable, beyond Milan criteria HCC. The inclusion criteria were a single tumor ≤6.5 cm or ≤5 tumors and all tumors ≤5 cm based on initial radiologic findings. We excluded patients with double primary cancers, age >60 years, vascular invasion, or extrahepatic spread. Survival rates were calculated using the Kaplan-Meier method. Multivariate analysis showed that TACE was a prognostic factor for survival (hazard ratio, 16.66, P =.000). The LT group showed significantly better survival than the TACE cohort. Two cases (16.7%) in the LT group recurred at a median time of 13.5 months. Survival rates at 1, 3, and 5 years were 100%, 88.9%, and 76.2% in the LT group, and 85.6%, 45.6%, and 21.4% in the TACE group, respectively. Patients with unresectable, beyond Milan criteria HCC should be given the option to receive LDLT, because LT offers a significantly better likelihood of survival than TACE.
UR - https://www.scopus.com/pages/publications/77955497082
U2 - 10.1016/j.transproceed.2010.02.027
DO - 10.1016/j.transproceed.2010.02.027
M3 - Article
C2 - 20430181
AN - SCOPUS:77955497082
SN - 0041-1345
VL - 42
SP - 821
EP - 824
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 3
ER -
